Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04164966 · ClinicalTrials.gov registry record
Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes
A clinical trial of Type 1 Diabetes, sponsored by AdventHealth Translational Research Institute.
- Active
- Registry status
- 28
- Enrollment target
- 1
- Study location
NCT04164966: Active study of Type 1 Diabetes, sponsored by AdventHealth Translational Research Institute.
NCT04164966 is a study of Type 1 Diabetes that is active but no longer recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 28 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04164966, a study of Type 1 Diabetes, is active but no longer recruiting, sponsored by AdventHealth Translational Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the levels of certain substances (biomarkers) in the body that may indicate the triggers of Type 1 Diabetes, to find a better way to diagnose the disease, as well as to follow its progression.
Primary Outcome
Measure will be the number (concentration) of circulating beta-cell specific exosomes. If the characterization of circulating beta-cell specific exosomes is not feasible in children with T1D due to the potentially limited low input amount of this type of exosomes in the circulation of these participants, an alternative analysis will be implemented.
Conditions Studied
Study Locations (1)
Florida
- AdventHealth Translational Research Institute - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-11-27 |
| Est. Completion | 2025-12 |
What the registry record for NCT04164966 still lists
NCT04164966 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 0 interventions.
NCT04164966 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04164966 about?
NCT04164966 is a clinical study titled "Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes". The purpose of this study is to measure the levels of certain substances (biomarkers) in the body that may indicate the triggers of Type 1 Diabetes, to find a better way to diagnose the disease, as well as to follow its progression.
What is the current status of trial NCT04164966?
This trial is currently active not recruiting. The enrollment target is 28 participants. The study started on 2019-11-27. Estimated completion is 2025-12.
What conditions does trial NCT04164966 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
Who is sponsoring clinical trial NCT04164966?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04164966 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04164966's enrollment target sits among peer trials
28 132nd of 198 higher than 65 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress
RECRUITING
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
AIDANET Pediatrics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI